Autonomic Technologies, Inc.
8
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
17%
1 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache
Role: lead
Pathway CH S&E Registry
Role: lead
Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
Role: lead
Pathway M-1: Sphenopalatine Ganglion Stimulation for the AcuteTreatment of High Disability Migraine Headache
Role: lead
Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches
Role: collaborator
Pathway CH-1 Long-Term Follow-Up
Role: lead
Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache
Role: lead
Cephalic Vascular Recording Upon SPG Stimulation
Role: lead
All 8 trials loaded